Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
•••••@invirsa.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••
Free to start · No credit card required
Current company Invirsa, Inc
Pharmaceutical Manufacturing · 11 employees · Columbus, Ohio, United States
The Problem: Diabetes damages the eye at the genomic level. Chronic hyperglycemia causes pathological PARylation — a \'molecular clog\' that disables CTCF, the architectural regulator of the genome, locking critical repair genes (p53, Pax6, BRCA1/2, XPC) in an inactive state. The result: non-healing corneal ulcers, progressive keratopathy, vision loss, and diabetic retinopathy. No approved therapy addresses this root cause. The Solution — INV-102: INV-102 (DiLithium ADP-ribose) is a first-in-class small molecule that competitively displaces pathological PAR chains, restoring CTCF-TAD loop architecture, the cell\'s \'Repair Chamber.\' This triggers coordinated upregulation of p53, Sirt6, and Pax6; transforming chronically damaged tissue into a rapidly healing one. Unlike anti-inflammatory or tear-supplement approaches, INV-102 addresses the underlying genomic dysfunction driving multiple diseases. Clinical Evidence: INV-102 has demonstrated statistically significant improvement in Best Corrected Visual Acuity (BCVA) vs. vehicle in diabetic subjects (p<0.01) in a randomized Phase 2 study. Results exclusively driven by the diabetic subpopulation, confirming mechanism specificity. Phase 2 data also show benefits in acute infectious keratoconjunctivitis (AIK), with a notable effect suggesting innate immune modulation. A Phase 2a pilot in diabetic macular edema / NPDR has been completed (NCT06••••84).